Sustenna to Trinza Transition Requirements
You need at least 4 monthly Sustenna injections before transitioning to Trinza. This is the FDA-mandated requirement to ensure adequate stabilization on the monthly formulation before switching to the quarterly extended-release product 1.
Transition Protocol
The FDA label for Trinza explicitly states: "Use INVEGA TRINZA only after the patient has been adequately treated with the 1-month paliperidone palmitate extended-release injectable suspension for at least four months" 1.
Dosing Conversion
When transitioning after 4+ months of Sustenna, initiate Trinza when the next monthly Sustenna dose is scheduled, using the following conversions 1:
- Sustenna 78 mg → Trinza 273 mg
- Sustenna 117 mg → Trinza 410 mg
- Sustenna 156 mg → Trinza 546 mg
- Sustenna 234 mg → Trinza 819 mg
Note: Conversion from Sustenna 39 mg was not studied and is not recommended 1.
Critical Considerations
The 4-month stabilization period serves multiple purposes:
- Confirms patient tolerability and response to paliperidone
- Establishes appropriate dosing before committing to a 3-month formulation
- Allows for dose adjustments on the more flexible monthly schedule
- Reduces risk of prolonged exposure to an ineffective or poorly tolerated dose
Administration requirements for Trinza:
- Must be given every 3 months (quarterly)
- Requires vigorous shaking for at least 15 seconds (longer than Sustenna)
- Intramuscular injection only (deltoid or gluteal)
- Must use the specific thin-wall needles provided in the kit 1
Managing Missed Doses
If transitioning is delayed beyond the scheduled timeframe, specific re-initiation protocols apply based on how long has elapsed since the last injection 1.